AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26198205 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 5384
Study 26198205 — intervention group
Group type: COMPARATOR
Intervention: BE
Number of subjects: 5384
Study 23250561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and stress self-management intervention (PASS)
Number of subjects: 77
Study 21360715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg alone
Number of subjects: 10
Study 21360715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg and itraconazole 200 mg combination
Number of subjects: 10
Study 21360715 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg alone
Number of subjects: 10
Study 19217538 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program for 2-9 weeks (Group A)
Number of subjects: 84
Study 19217538 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program for 10-14 weeks (Group B)
Number of subjects: 84
Study 19217538 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program for 15-94 weeks (Group C)
Number of subjects: 84
Study 17786886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium long-term treatment
Number of subjects: 0
Study 17786886 — intervention group
Group type: COMPARATOR
Intervention: Other mood stabilizers and antidepressants
Number of subjects: 0
Study 15252707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine oestrogens plus 2.5 mg medroxyprogesterone acetate
Number of subjects: 15641
Study 15252707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15641
Study 11384692 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy
Number of subjects: 25
Study 11384692 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive women)
Number of subjects: 25
Study 11384692 — intervention group
Group type: COMPARATOR
Intervention: Control (newborns from normotensive women)
Number of subjects: 25
Study 11384692 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclamptic women
Number of subjects: 25
Study 11384692 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns from preeclamptic women
Number of subjects: 25
Study 9401132 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced dysphoria (Study 1)
Number of subjects: 0
Study 9401132 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally occurring dysphoria (Study 2)
Number of subjects: 0
Study 9401132 — intervention group
Group type: COMPARATOR
Intervention: Pre-conscious bias (14 ms exposure condition)
Number of subjects: 0
Study 9401132 — intervention group
Group type: COMPARATOR
Intervention: High trait anxiety (Study 2)
Number of subjects: 0
Study 8495532 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya milk preparations
Number of subjects: 19
Study 8495532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein milk
Number of subjects: 19
Study 8495532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary change to soya milk
Number of subjects: 19
Study 3446365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10 micrograms.kg-1.min-1)
Number of subjects: 20
Study 3446365 — intervention group
Group type: COMPARATOR
Intervention: Felodipine (5-10 mg)
Number of subjects: 20
Study 2573003 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 24
Study 2573003 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg Madopar
Number of subjects: 24
Study 2573003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31596866 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief 3-week diet intervention (Diet Group)
Number of subjects: 101
Study 31596866 — intervention group
Group type: COMPARATOR
Intervention: Control Group (habitual diet)
Number of subjects: 101
Study 31596866 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Group
Number of subjects: 101
Study 28086784 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cardiac Rehabilitation Programme (MCRP)
Number of subjects: 112
Study 28086784 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cardiac Rehabilitation Programme (CCRP)
Number of subjects: 112
Study 28086784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 25226311 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (8 g)
Number of subjects: 12
Study 25226311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 23195033 — intervention group
Group type: COMPARATOR
Intervention: 480 mg choline/d
Number of subjects: 26
Study 23195033 — intervention group
Group type: EXPERIMENTAL
Intervention: 930 mg choline/d
Number of subjects: 26
Study 21751250 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg per day for 12 weeks
Number of subjects: 59
Study 21751250 — intervention group
Group type: COMPARATOR
Intervention: Control group (MD without cancer)
Number of subjects: 59
Study 19288247 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid regimen (group S, n=21)
Number of subjects: 41
Study 19288247 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid regimen (group R, n=20)
Number of subjects: 41
Study 16728541 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 98
Study 16728541 — intervention group
Group type: EXPERIMENTAL
Intervention: DII polymorphism (Thr92Ala)
Number of subjects: 98
Study 15567471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ppm chlorine exposure for 15 min
Number of subjects: 16
Study 15567471 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure for 15 min
Number of subjects: 16
Study 10620131 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomes containing T4 endonuclease V
Number of subjects: 15
Study 10620131 — intervention group
Group type: COMPARATOR
Intervention: Heat-inactivated enzyme (Control)
Number of subjects: 15
Study 9370180 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of aluminum kitchen utensils with stainless steel utensils for 3 months (study group)
Number of subjects: 42
Study 9370180 — intervention group
Group type: COMPARATOR
Intervention: Aluminum kitchen utensils continued (control group)
Number of subjects: 42
Study 9370180 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group patients with greater decrements of serum aluminum (>5.5 microg/L)
Number of subjects: 42
Study 9370180 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group patients with less decrements of serum aluminum (<5.5 microg/L)
Number of subjects: 42
Study 8336377 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 602
Study 3570859 — intervention group
Group type: EXPERIMENTAL
Intervention: Four types of milk with normal or low lactose and/or fat content, increasing amounts (125, 250, 500, 1000 ml/d)
Number of subjects: 80
Study 3570859 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing amounts of milk (125, 250, 500, 1000 ml/d)
Number of subjects: 80
Study 3570859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat content in milk
Number of subjects: 80
Study 3570859 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences
Number of subjects: 80
Study 31554379 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring quality of life intervention using the Care Notebook booklet
Number of subjects: 43
Study 31554379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 43
Study 28024961 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 100mg bid (up-titrated to 200mg bid)
Number of subjects: 220
Study 28024961 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5mg bid (up-titrated to 10mg bid)
Number of subjects: 220
Study 26805496 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (8 weeks, 15 sessions)
Number of subjects: 37
Study 24091268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 110
Study 24091268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 21431329 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of 200 mg mifepristone orally and 400 μg misoprostol vaginally
Number of subjects: 80
Study 21431329 — intervention group
Group type: COMPARATOR
Intervention: Administration of 200 mg mifepristone orally and 400 μg misoprostol vaginally at 24-h interval
Number of subjects: 80
Study 21431329 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of 200 mg mifepristone and 400 μg misoprostol
Number of subjects: 80
Study 21431329 — intervention group
Group type: COMPARATOR
Intervention: Administration of 200 mg mifepristone and 400 μg misoprostol at 24-h interval
Number of subjects: 80
Study 18364535 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental group (DEV)
Number of subjects: 45
Study 18364535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation group (C-V)
Number of subjects: 45
Study 16792289 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG/ECoG signals from nonparalyzed subjects
Number of subjects: 16
Study 16792289 — intervention group
Group type: COMPARATOR
Intervention: EEG/ECoG signals from paralyzed subjects
Number of subjects: 16
Study 12710222 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinflected irregular verbs
Number of subjects: 0
Study 12710222 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of correct form
Number of subjects: 0
Study 12710222 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinflected form
Number of subjects: 0
Study 12710222 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinflected irregular verb
Number of subjects: 0
Study 10640159 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu-380A IUD
Number of subjects: 2748
Study 8964633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance assessment during hemodialysis
Number of subjects: 0
Study 1839430 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulphate 100 mg per os, b.i.d.
Number of subjects: 50
Study 1839430 — intervention group
Group type: COMPARATOR
Intervention: Mesoglycan 50 mg per os, t.i.d.
Number of subjects: 50
Study 6756666 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin SC 200 UI 6-hourly for 48 hours
Number of subjects: 25
Study 6756666 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25
Study 30385039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone (0.5 mg/kg/day, maximum 40 mg/day) plus enteric-coated mycophenolate sodium 720 mg twice daily for 24 weeks
Number of subjects: 116
Study 30385039 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-dose prednisone (1 mg/kg/day, maximum 80 mg/day) for 24 weeks
Number of subjects: 116
Study 30385039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone plus enteric-coated mycophenolate sodium
Number of subjects: 116
Study 30385039 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-dose prednisone
Number of subjects: 116
Study 30385039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 27037432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Number of subjects: 36
Study 27037432 — intervention group
Group type: COMPARATOR
Intervention: Non-ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Number of subjects: 36
Study 25158081 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT patches (15 mg per 16 hours) for 8 weeks
Number of subjects: 1050
Study 25158081 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study 25158081 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT patches
Number of subjects: 1050
Study 22167121 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention (asthma education, motivational interviewing, problem-solving skills training, 1 month cell-phone with tailored text messaging)
Number of subjects: 26
Study 22167121 — intervention group
Group type: COMPARATOR
Intervention: Control (asthma education; cell-phone without tailored messaging)
Number of subjects: 26
Study 20346057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 or 45 mg)
Number of subjects: 60
Study 20346057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19015469 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan, 12 mg, administered orally 30 to 90 minutes preoperatively and twice daily postoperatively
Number of subjects: 0
Study 19015469 — intervention group
Group type: COMPARATOR
Intervention: Standardized accelerated postoperative care pathway alone (Placebo)
Number of subjects: 0
Study 19015469 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan, 12 mg
Number of subjects: 0
Study 19015469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16044840 — intervention group
Group type: EXPERIMENTAL
Intervention: Athenolol (50 mg daily) with antiatherogenic lactoovovegetarian diet
Number of subjects: 84
Study 16044840 — intervention group
Group type: COMPARATOR
Intervention: Athenolol (50 mg daily) with standard antiatherogenic diet
Number of subjects: 84
Study 16044840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotiazide (25 mg daily) with antiatherogenic lactoovovegetarian diet
Number of subjects: 84
Study 16044840 — intervention group
Group type: COMPARATOR
Intervention: Hypotiazide (25 mg daily) with standard antiatherogenic diet
Number of subjects: 84
Study 12444212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg)
Number of subjects: 16
Study 12444212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg) and Amiloride (5 mg) combination
Number of subjects: 16
Study 12444212 — intervention group
Group type: COMPARATOR
Intervention: Amiloride (5 mg)
Number of subjects: 16
Study 12444212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 16
Study 12444212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone and Amiloride combination
Number of subjects: 16
Study 9660361 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of indinavir, zidovudine, and lamivudine
Number of subjects: 97
Study 9660361 — intervention group
Group type: COMPARATOR
Intervention: Sequential initiation of zidovudine and lamivudine
Number of subjects: 97
Study 9660361 — intervention group
Group type: COMPARATOR
Intervention: Sequential initiation of indinavir
Number of subjects: 97
Study 8620678 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 800mg administered twice daily from day 4 to day 8
Number of subjects: 14
Study 8620678 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily from day 4 to day 8
Number of subjects: 14
Study 2568519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (6 g/day of n-3 fatty acids) for 6 months, starting 5.4 days before PTCA.
Number of subjects: 204
Study 2568519 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo (control group).
Number of subjects: 204
Study 779756 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking (0.739 g)
Number of subjects: 10
Study 779756 — intervention group
Group type: COMPARATOR
Intervention: Placebo smoking (0.739 g)
Number of subjects: 10
Study 779756 — intervention group
Group type: COMPARATOR
Intervention: No smoking control period
Number of subjects: 10
Study 29023326 — intervention group
Group type: EXPERIMENTAL
Intervention: SS + ES
Number of subjects: 31
Study 29023326 — intervention group
Group type: EXPERIMENTAL
Intervention: SS
Number of subjects: 31
Study 29023326 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 28682745 — intervention group
Group type: EXPERIMENTAL
Intervention: Community resource mapping intervention
Number of subjects: 11
Study 25539730 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1502
Study 25539730 — intervention group
Group type: COMPARATOR
Intervention: ABV (doxorubicin, bleomycin, and vinblastine)
Number of subjects: 1502
Study 25539730 — intervention group
Group type: COMPARATOR
Intervention: AVD (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 1502
Study 25539730 — intervention group
Group type: COMPARATOR
Intervention: AV (doxorubicin and vinblastine)
Number of subjects: 1502
Study 23647307 — intervention group
Group type: EXPERIMENTAL
Intervention: IWT plus post-exercise macronutrient supplementation (7.6 g protein, 32.5 g carbohydrate, and 4.4 g fat)
Number of subjects: 35
Study 23647307 — intervention group
Group type: COMPARATOR
Intervention: IWT alone (CNT)
Number of subjects: 35
Study 21521915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 0
Study 21521915 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% povidone iodine
Number of subjects: 0
Study 21521915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite
Number of subjects: 0
Study 21521915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% hydrogen peroxide followed by 2% sodium hypochlorite
Number of subjects: 0
Study 21521915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite alone
Number of subjects: 0
Study 19210009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively based extension of the Healthy Start home visitation program (HV+)
Number of subjects: 102
Study 19210009 — intervention group
Group type: COMPARATOR
Intervention: Visitation condition without the cognitive component (HV)
Number of subjects: 102
Study 17097995 — intervention group
Group type: EXPERIMENTAL
Intervention: Two bolus doses of daclizumab (1 mg/kg) on days 1 and 14 posttransplantation
Number of subjects: 81
Study 17097995 — intervention group
Group type: COMPARATOR
Intervention: Five bolus doses of daclizumab (1 mg/kg) every 14 days
Number of subjects: 81
Study 17097995 — intervention group
Group type: EXPERIMENTAL
Intervention: Two bolus doses of daclizumab
Number of subjects: 81
Study 17097995 — intervention group
Group type: COMPARATOR
Intervention: Five bolus doses of daclizumab
Number of subjects: 81
Study 14746621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse-off product containing methyldibromoglutaronitrile (MDBGN)
Number of subjects: 28
Study 14746621 — intervention group
Group type: COMPARATOR
Intervention: Rinse-off product without methyldibromoglutaronitrile (MDBGN)
Number of subjects: 28
Study 11269572 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GJ)
Number of subjects: 22
Study 11269572 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 22
Study 9230827 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal photocoagulation
Number of subjects: 109
Study 9230827 — intervention group
Group type: EXPERIMENTAL
Intervention: Very severe hard exudates
Number of subjects: 109
Study 8548226 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (300 units/kg as first administration, and 100 units/kg 4, 8 and 12 days later) with supplemental iron
Number of subjects: 22
Study 8548226 — intervention group
Group type: COMPARATOR
Intervention: Iron saccharate 200 mg/day intravenously for 12 consecutive days
Number of subjects: 22
Study 2596436 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate diet (Zn-Cu ratio 2:1)
Number of subjects: 15
Study 2596436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Zn diet (Zn-Cu ratio 15:1)
Number of subjects: 15
Study 2596436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Cu diet (Zn-Cu ratio 5:1)
Number of subjects: 15
Study 2596436 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted Cu diet
Number of subjects: 15
Study 65273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg delta9‐tetrahydrocannabinol (THC)
Number of subjects: 12
Study 65273 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg 95% ethanol
Number of subjects: 12
Study 65273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 65273 — intervention group
Group type: EXPERIMENTAL
Intervention: Set size
Number of subjects: 12
Study 31834549 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially expressed circRNAs in Alzheimer's disease patients
Number of subjects: 5
Study 31834549 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 10 upregulated and downregulated circRNAs
Number of subjects: 5
Study 31834549 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene ontology and KEGG pathway analyses
Number of subjects: 5
Study 31834549 — intervention group
Group type: EXPERIMENTAL
Intervention: circRNA‐miRNA‐mRNA network
Number of subjects: 5
Study 30916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (SB)
Number of subjects: 0
Study 30916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (SPB)
Number of subjects: 0
Study 30916412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27841942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 692
Study 27841942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 692
Study 24385118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cosmetic formulation containing N-acetyl tyrosinamide
Number of subjects: 70
Study 24385118 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 70
Study 24385118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cosmetic formulation
Number of subjects: 70
Study 22755344 — intervention group
Group type: EXPERIMENTAL
Intervention: Back care education programme
Number of subjects: 0
Study 22755344 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20708904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular levetiracetam (500mg, 5ml)
Number of subjects: 10
Study 20708904 — intervention group
Group type: COMPARATOR
Intervention: Intravenous levetiracetam
Number of subjects: 10
Study 18368612 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonist pharmacotherapy (specific agonists not detailed)
Number of subjects: 0
Study 18368612 — intervention group
Group type: COMPARATOR
Intervention: Indirect agonists (dexamphetamine and methylphenidate)
Number of subjects: 0
Study 16299646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 150,000 U per day for 5 days
Number of subjects: 40